AzTrials
AzTrials

Acute Ischemic StrokePhase 2FRUCTOSE-AISNCT07626541

Fructose for Acute Ischemic Stroke

A Phase 2 study testing 10% Fructose Injection in people with Acute Ischemic Stroke, run by Ji Xunming,MD,PhD at 1 site in China.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This is a single-center, prospective, randomized, open-label, blinded-endpoint exploratory clinical study enrolling 46 patients with acute ischemic stroke. All eligible patients have symptom onset within 4.5 hours, meet intravenous thrombolysis indications, and receive standard thrombolysis and routine stroke… Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Acute Ischemic Stroke
What is being tested?
10% Fructose Injection
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
46 participants
Where
1 siteChina
Study dates
5 Jun 2026to Aug 2026
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aged between 18 and 85 years, male and female are both eligible.
  • Clinical diagnosis of acute ischemic stroke meeting the diagnostic criteria of Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke.
  • Time from stroke onset to hospital admission ≤ 4.5 hours, with new ischemic lesions confirmed by emergency multimodal cranial MRI (DWI/T2WI).
  • Meeting the indications for intravenous thrombolysis, without absolute contraindications to thrombolysis, and planned to receive standard intravenous thrombolysis.
  • Relatively stable vital signs, able to complete baseline and follow-up cranial MRI examinations including DWI, T2WI and ¹H-MRS, as well as NIHSS and mRS scale assessments.
  • The patient or legal representative voluntarily participates in the study and signs written informed consent.

Who cannot join

  • History of fructose intolerance, abnormal fructose metabolism or hereditary fructose metabolic disorders.
  • History of diabetes mellitus or random blood glucose > 11.1 mmol/L.
  • Evidence of intracranial hemorrhage on CT scan, symptomatic intracranial hemorrhage, or clinical suspicion of subarachnoid hemorrhage.
  • Requiring or intending to continue using restricted medications that may interfere with study safety and implementation.
  • Unable to complete cranial MRI examination due to implanted metal materials, claustrophobia or other reasons.
  • Any other conditions judged by the investigator to be inappropriate for enrollment.
Show all 23Show fewer
  • Presence of hemorrhagic diathesis, including but not limited to:
  • Known hereditary bleeding tendency or severe bleeding disease within the past 6 months;
  • Received heparin within 48 hours before enrollment with aPTT exceeding the upper limit of laboratory reference range;
  • Current use of vitamin K-dependent oral anticoagulants with INR > 1.7 or PT > 15 s, or current use of novel oral anticoagulants with prolonged aPTT/PT above laboratory upper limit;
  • Platelet count < 100,000/mm³ at screening;
  • History of central nervous system diseases such as tumor, aneurysm, intracranial or spinal surgery;
  • Received traumatic closed-chest cardiac massage, obstetric delivery or non-compressible vascular puncture within the past 10 days;
  • Suspected intracranial hemorrhage or aneurysmal subarachnoid hemorrhage;
  • Tumors with increased bleeding risk;
  • Peptic ulcer disease, esophageal varices, aneurysm, arterial/venous malformation within the past 3 months;
  • Any other known diseases associated with significantly elevated bleeding risk.
  • Pre-stroke mRS score ≥ 2, combined with dementia or other neurological disabling diseases.
  • Complicated with severe medical history affecting endpoint evaluation and follow-up, such as craniocerebral trauma, multiple sclerosis, encephalitis, tumor, poisoning, syphilis, or severe cardiac, pulmonary, hepatic, renal and endocrine diseases.
  • Pregnant females.
  • Currently participating in another investigational drug or device study, or participation in other experimental treatment within less than 30 days prior to enrollment.
  • Combined with severe hepatic and renal insufficiency (eGFR < 30 mL/min/1.73m²).
  • Refusal to sign informed consent.

Trial locations and contacts

1 site in 1 country.

China1 site

  • Xuzhou Medical University Affiliated Hospital

    Xuzhou, Jiangsu, 221000

Other trials in China

About this study

Official title: Clinical Study of Fructose Injection in the Treatment of Acute Ischemic Stroke

This is a single-center, prospective, randomized, open-label, blinded-endpoint exploratory clinical study enrolling 46 patients with acute ischemic stroke. All eligible patients have symptom onset within 4.5 hours, meet intravenous thrombolysis indications, and receive standard thrombolysis and routine stroke treatment. Participants are randomly assigned to two groups: the intervention group receives early intravenous infusion of 10% fructose injection plus standard treatment, while the control group receives only standard treatment without fructose. The study mainly evaluates changes in neurological function via NIHSS scores within 7 days after thrombolysis, assesses cerebral infarct lesion volume and brain edema using multimodal MRI including DWI, T2WI and MRS, detects cerebral neuronal metabolic markers, and conducts 1-month follow-up of neurological function by NIHSS score as well as functional prognosis using the mRS score. The research also comprehensively monitors adverse events and safety indicators to explore the clinical efficacy, neuronal metabolic regulation effect and safety of early fructose injection combined with intravenous thrombolysis in acute ischemic stroke patients, aiming to provide clinical evidence for early neuroprotective intervention.

Read the detailed description

This is an investigator-initiated, single-center, prospective, randomized, open-label, blinded-endpoint (PROBE) exploratory clinical trial. A total of 46 eligible patients with acute ischemic stroke within 4.5 hours of onset who meet the indications for intravenous thrombolysis will be enrolled. Participants are randomly assigned to an intervention group and a control group.The intervention group receives early intravenous infusion of 250 mL 10% fructose injection combined with standard intravenous thrombolysis and routine stroke background treatment. The control group receives only standard intravenous thrombolysis and conventional medical therapy without fructose intervention. All patients undergo standardized blood pressure and blood glucose management, and antiplatelet therapy is initiated 24 hours after thrombolysis.Neurological function is repeatedly assessed using the National Institutes of Health Stroke Scale (NIHSS) every 12 hours within 72 hours after thrombolysis and daily thereafter. Multimodal brain magnetic resonance examinations including DWI, T2WI and MRS are performed to evaluate cerebral infarct lesion volume, cerebral edema, and neuronal metabolic biomarkers such as NAA, Cho and Lac. The primary outcome is the change in NIHSS score at 7 days after thrombolysis, and cerebral neuronal metabolic characteristics. Secondary outcomes include dynamic neurological recovery, imaging changes of ischemic lesions, 1-month NIHSS score, 1-month modified Rankin Scale (mRS) functional prognosis.Prespecified subgroup analyses are conducted according to baseline neurological deficit severity, age, hypertension history and gender. Safety outcomes monitor adverse events such as hemorrhagic transformation, allergic reactions, liver and renal function abnormalities, blood glucose and electrolyte disorders to evaluate the clinical safety and tolerability of early fructose combined with thrombolysis.An independent clinical endpoint adjudication committee blindly assesses all endpoint events to reduce evaluation bias. Statistical analyses adopt appropriate methods for non-equilibrium small sample data to explore the clinical efficacy, neuronal mitochondrial metabolic regulation mechanism and safety of early fructose injection intervention in acute ischemic stroke patients, so as to provide clinical evidence for early neuroprotective strategy optimization.

Being tested
10% Fructose Injection
Keywords
Acute ischemic stroke, Fructose, Intravenous thrombolysis, Neuroprotection, NIHSS, Brain magnetic resonance spectroscopy, Cerebral energy metabolism
Medical subject headings
Ischemic Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 10% Fructose InjectionDrug

    Single intravenous infusion of 250 mL 10% fructose injection administered as early as possible within the ischemic stage, combined with standard intravenous thrombolysis and standardized basic treatment for acute ischemic stroke. Unified blood pressure and blood glucose management are implemented, and antiplatelet therapy is started 24 hours after thrombolysis.

Study groups in NCT07626541
Study groupRoleWhat they receive
Fructose Injection plus Standard Thrombolysis TreatmentExperimentalPatients receive early intravenous infusion of 250 mL 10% fructose injection immediately after admission, followed by standard intravenous thrombolysis and routine standardized medical treatment for acute ischemic stroke. Unified blood pressure and blood glucose management are performed in all participants, and antiplatelet therapy is initiated 24 hours after thrombolysis.
Receives: Drug: 10% Fructose Injection
Standard Thrombolysis Alone Without FructoseNo interventionPatients receive only standard intravenous thrombolysis and routine standardized medical treatment for acute ischemic stroke without additional fructose injection. All participants receive the same unified blood pressure, blood glucose control and antiplatelet therapy regimen as the intervention group.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 7-day change in National Institutes of Health Stroke Scale (NIHSS) score

    Absolute change in NIHSS score, calculated as follow-up score minus pre-intravenous thrombolysis (pre-IVT) baseline score, assessed at 7 days after intravenous thrombolysis (IVT). The full scale is the National Institutes of Health Stroke Scale; total score ranges from 0 to 42, and higher scores indicate more severe neurological deficits.

    Measured: Baseline to 7 days after thrombolysis

Secondary outcomes (7)

  1. Levels of N-acetylaspartate (NAA) detected by proton magnetic resonance spectroscopy (¹H-MRS)

    Absolute changes in the levels of N-acetylaspartate (NAA) in the ischemic penumbra and infarct core, calculated from pre-IVT baseline to 24 hours after IVT. Relative quantification; no absolute concentration determined. Metabolite signal intensities are reported in arbitrary units (a.u.) normalized to internal reference (e.g., total NAA or water signal).

    Unit of measure: Arbitrary units

    Measured: Pre-IVT baseline to 24 hours post-IVT (±2 hours)

  2. Levels of choline (Cho) detected by proton magnetic resonance spectroscopy (¹H-MRS)

    Absolute changes in the levels of choline (Cho) in the ischemic penumbra and infarct core, calculated from pre-IVT baseline to 24 hours after IVT. Relative quantification; no absolute concentration determined. Metabolite signal intensities are reported in arbitrary units (a.u.) normalized to internal reference (e.g., total Cho or water signal).

    Unit of measure: Arbitrary units

    Measured: Time Frame: Pre-IVT baseline to 24 hours post-IVT (±2 hours)

  3. Levels of creatine (Cr) detected by proton magnetic resonance spectroscopy (¹H-MRS)

    Absolute changes in the levels of creatine (Cr) in the ischemic penumbra and infarct core, calculated from pre-IVT baseline to 24 hours after IVT. Relative quantification; no absolute concentration determined. Metabolite signal intensities are reported in arbitrary units (a.u.) normalized to internal reference (e.g., total Cr or water signal).

    Arbitrary units

    Measured: Pre-IVT baseline to 24 hours post-IVT (±2 hours)

  4. NAA/Cr ratio derived from ¹H-MRS

    Absolute change in N-acetylaspartate/creatine (NAA/Cr) ratio in the ischemic penumbra and infarct core, calculated from pre-IVT baseline to 24 hours after IVT.

    Unit of measure: Ratio (no unit)

    Measured: Pre-IVT baseline to 24 hours post-IVT (±2 hours)

  5. Cho/Cr ratio derived from ¹H-MRS

    Absolute change in choline/creatine (Cho/Cr) ratio in the ischemic penumbra and infarct core, calculated from pre-IVT baseline to 24 hours after IVT.

    Time Frame: Pre-IVT baseline to 24 hours post-IVT (±2 hours). Unit of measure: Ratio (no unit)

    Measured: Time Frame: Pre-IVT baseline to 24 hours post-IVT (±2 hours)

  6. 1-month change in National Institutes of Health Stroke Scale (NIHSS) score

    Absolute change in NIHSS score, calculated as follow-up score minus pre-IVT baseline score, assessed at 1 month after IVT. The full scale is the National Institutes of Health Stroke Scale; total score ranges from 0 to 42, and higher scores indicate more severe neurological deficits.

    Measured: Pre-IVT baseline to 1 month post-IVT (±7 days)

  7. 1-month functional outcome assessed by modified Rankin Scale (mRS)

    Description: Functional status classified into favorable and unfavorable outcomes at 1 month after IVT. Favorable outcome: mRS score 0-2 (no or mild disability, independent in activities of daily living). Unfavorable outcome: mRS score 3-6 (moderate to severe disability, dependent in activities of daily living, or death for mRS score 6). The full scale is the modified Rankin Scale; total score ranges from 0 to 6, and higher scores indicate greater functional disability.

    Measured: Pre-IVT baseline to 1 month post-IVT (±7 days)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jun 2026
  2. Study start5 Jun 2026
  3. Primary completionAug 2026 (estimated)
  4. Study completionAug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This study adopts a parallel-group design. Eligible participants are randomly assigned to either the intervention group receiving 10% fructose injection combined with standard intravenous thrombolysis and routine stroke treatment, or the control group receiving only standard intravenous thrombolysis and conventional medical management without fructose intervention. The two groups are followed up in parallel to compare neurological function recovery, imaging changes, cerebral neuronal metabolism and safety outcomes.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
46 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07626541
Sponsor's protocol ID
AIS-FRUCTOSE
Acronym
FRUCTOSE-AIS
Status last verified
Jun 2026
First submitted
23 May 2026
Last updated
18 Jun 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: A definitive plan for sharing individual participant data (IPD) has not yet been established at this stage. The feasibility and specific modalities of IPD sharing will be further evaluated and determined based on study progress, ethics committee approval, and relevant regulatory requirements.

Publications

  • Zhang D, Feng Y, Pan H, Xuan Z, Yan S, Mao Y, Xiao X, Huang X, Zhang H, Zhou F, Chen B, Chen X, Liu H, Yan X, Liang H, Cui W. 9-Methylfascaplysin exerts anti-ischemic stroke neuroprotective effects via the inhibition of neuroinflammation and oxidative stress in rats. Int Immunopharmacol. 2021 Aug;97:107656. doi: 10.1016/j.intimp.2021.107656. Epub 2021 Apr 23.

    PubMed 33895476

  • Tian Y, Su Y, Ye Q, Chen L, Yuan F, Wang Z. Silencing of TXNIP Alleviated Oxidative Stress Injury by Regulating MAPK-Nrf2 Axis in Ischemic Stroke. Neurochem Res. 2020 Feb;45(2):428-436. doi: 10.1007/s11064-019-02933-y. Epub 2019 Dec 19.

    PubMed 31858374

  • Marek G, Pannu V, Shanmugham P, Pancione B, Mascia D, Crosson S, Ishimoto T, Sautin YY. Adiponectin resistance and proinflammatory changes in the visceral adipose tissue induced by fructose consumption via ketohexokinase-dependent pathway. Diabetes. 2015 Feb;64(2):508-18. doi: 10.2337/db14-0411. Epub 2014 Sep 3.

    PubMed 25187370

  • Kim YN, Jung HY, Eum WS, Kim DW, Shin MJ, Ahn EH, Kim SJ, Lee CH, Yong JI, Ryu EJ, Park J, Choi JH, Hwang IK, Choi SY. Neuroprotective effects of PEP-1-carbonyl reductase 1 against oxidative-stress-induced ischemic neuronal cell damage. Free Radic Biol Med. 2014 Apr;69:181-96. doi: 10.1016/j.freeradbiomed.2014.01.006. Epub 2014 Jan 17.

    PubMed 24440593

  • Hayasaki T, Ishimoto T, Doke T, Hirayama A, Soga T, Furuhashi K, Kato N, Kosugi T, Tsuboi N, Lanaspa MA, Johnson RJ, Maruyama S, Kadomatsu K. Fructose increases the activity of sodium hydrogen exchanger in renal proximal tubules that is dependent on ketohexokinase. J Nutr Biochem. 2019 Sep;71:54-62. doi: 10.1016/j.jnutbio.2019.05.017. Epub 2019 Jun 8.

    PubMed 31276916

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing 10% Fructose Injection in people with Acute Ischemic Stroke, run by Ji Xunming,MD,PhD at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

7-day change in National Institutes of Health Stroke Scale (NIHSS) score (time frame: Baseline to 7 days after thrombolysis). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07626541, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in